- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04018248
BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I)
A Phase I, Open-label, Multi-center, Dose Escalation, and Expansion Study of BR101801 in Adult Patients With Advanced Hematologic Malignancies
This is a Phase I-II, multi-center, open-label, FIH study comprising of 2 study parts (Phase Ia, Phase Ib).
The Phase Ia (dose escalation) part of the study is designed to determine the safety, tolerability, and maximum tolerated dose (MTD)/recommended dose for expansion (RP2D) of BR101801 in subjects with relapsed/refractory B cell lymphoma, chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), and peripheral T cell lymphoma (PTCL).
The Phase Ib (dose expansion) part of the study is designed to assess tumor response and safety in specific advanced relapsed/refractory Peripheral T-cell lymphoma(PTCL) at a dose of BR101801 identified in Phase Ia. Once the RP2D has been determined in Phase Ia (dose escalation), Phase Ib (dose expansion) will commence.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Phase Ia (Dose Escalation)
Primary Objectives
- To assess the safety and tolerability of BR101801 in patients with relapsed/refractory B-cell lymphoma, CLL/SLL, and PTCL.
- To assess DLT and to determine the MTD and/or the RDE dose for BR101801 when administered orally on a daily schedule in 4-week cycles until disease progression.
SecondaryObjectives
- To characterize the plasma and urine PK of BR101801.
- To assess the preliminary antitumor activity of BR101801.
- Phase Ib (Dose Expansion)
Primary Objectives
• To assess the safety and tolerability of BR101801 at the RP2D dose in subjects with relapsed/refractory Peripheral T-cell lymphoma (PTCL).
SecondaryObjectives
- To assess clinical activity of BR101801 when administered orally on a daily schedule in 4-week cycles until disease progression.
- To assess the plasma PK of BR101801.
OUTLINE: This is a Phase I, multi-center, open-label, FIH study. The safety monitoring committee(SMC) will be responsible for safety oversight.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Bong-Seog Kim
- Phone Number: +82-2-708-8204
- Email: seog9270@boryung.co.kr
Study Locations
-
-
-
Busan, Korea, Republic of
- Inje University Busan Paik Hospital
-
Seoul, Korea, Republic of
- Seoul National University Hospital
-
Seoul, Korea, Republic of
- Asan Medical Center
-
Seoul, Korea, Republic of
- Samsung Medical Center
-
Seoul, Korea, Republic of
- Severance Hospital, Yonsei University Health System
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, Korea, Republic of
- National Cancer Center
-
Seongnam-si, Gyeonggi-do, Korea, Republic of
- Seoul National University Bundang Hospital
-
-
Jeollanam-do
-
Hwasun, Jeollanam-do, Korea, Republic of
- Chonnam National University Hwasun Hospital
-
-
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
<Inclusion Criteria>
- Patients must sign an informed consent document
- Female or male patients aged ≥ 18 years.
- ECOG performance status ≤ 2.
- Life expectancy more than 3 months.
- Phase Ia:Patients with relapsed and/or refractory relapsed/refractory B-cell lymphoma, CLL/SLL, and PTCL diagnosed with World Health Organization (WHO) classification
- Phase Ib: Subjects with PTCL NOS, PTCL AITL, Nodal PTCL with TFH and PTCL FTCL.
- Patients have measurable disease based on the appropriate tumor type criteria( Phase Ib only)
- Have a current need for systemic therapy, the assessment of the investigator.
- An archival or fresh tumor tissue (ie, tissue block or series of at least 5 slides, up to 15 slides) is required and should be provided during the Screening Visit for Lymphoma subjects. Local review of pathology is required for study entry in Phase Ib only.
- Phase Ia subjects should be prepared to undergo a fresh tumor biopsy during the study (tumor biopsies will be obtained from 1 to 2 subjects per cohort in Phase Ia).
Subject having laboratory values defined as:
- Creatinine clearance (measured or calculated per institutional standard practice) ≥ 60 mL/min. GFR can also be used in place of creatinine clearance.
- Total bilirubin < 1.5 × ULN, except for subjects with Gilbert's syndrome who are excluded if total bilirubin > 3.0 × ULN or direct bilirubin < 1.5 × ULN.
- ALT < 2.5 × ULN, except for subjects who have tumor involvement of the liver, who are included if ALT < 5 × ULN.
- AST < 2.5 × ULN, except for subjects that have tumor involvement of the liver, who are included if AST < 5 × ULN.
- Absolute neutrophil count > 1.0 × 109/L.
- Platelet count > 75 × 109/L.
- Hemoglobin > 8 g/dL.
<Exclusion Criteria>
- Presence of overt leptomeningeal or active CNS metastases, or CNS metastases that require local CNS-directed therapy or increasing doses of corticosteroids within the prior 2 weeks. Patients with treated brain metastases should be neurologically stable and off steroids for at least 2 weeks before administration of any study treatment.
- Impaired cardiac function or clinically significant cardiac disease
- Patients with interstitial pneumonia or history of drug-induced interstitial pneumonia/pneumonitis.
- Human immunodeficiency virus (HIV) infection.
- Patients who are positive for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C virus antibody (HCVAb).
- Chronic liver disease or chronic hepatitis
- Any gastrointestinal disorders interfering with study drug absorption or are unable to swallow tablets or capsules.
- Malignant disease, other than that being treated in this study.
- Prior PI3K inhibitor will be accepted in the dose escalation part of the study (Phase Ia) only.
For patients with lymphoma:
- Systemic antineoplastic therapy (including cytotoxic chemotherapy, alfa-interferon [INF], and toxin immunoconjugates) or any experimental therapy within 3 weeks or 5 half lives, whichever is shorter, before the first dose of study treatment.
- Therapy with tyrosine kinase inhibitor within 5 half-lives before the first dose of study treatment.
- Unconjugated monoclonal antibody therapies < 6 weeks before the first dose of study treatment.
- Patients receiving systemic chronic steroid therapy or any immunosuppressive therapy (≥ 10 mg/day prednisone or equivalent).
- Use of any live vaccines against infectious diseases within 4 weeks of initiation of study treatment.
- Use of hematopoietic colony-stimulating growth factors, thrombopoietin mimetics, or erythroid-stimulating agents ≤ 2 weeks prior to start of study drug.
- Patients with a history of stroke or having active neurological symptoms, with the exception of chronic conditions which, in the opinion of the neurologist, Investigator, and the Sponsor, would not impact ongoing neurologic assessments while on study treatment.
- Active infection requiring systemic or antiviral antibiotic therapy.
- Subjects with active CMV infection.
- Subjects receiving moderate or potent CYP3A4 inhibitors or inducers and are unable to withdraw until 2 weeks or 5 times longer than the half-life, whichever is shorter, before the first dose of study treatment.
- Major surgery within 2 weeks of the first dose of study treatment (mediastinoscopy, insertion of a central venous access device, and insertion of a feeding tube are not considered major surgery).
- Radiotherapy within 2 weeks of the first dose of study treatment, except for palliative radiotherapy to a limited-field, such as for the treatment of bone pain or a focally painful tumor mass.
- Presence of CTCAE ≥ Grade 2 toxicity (except alopecia, peripheral neuropathy, and ototoxicity, which are excluded if ≥ CTCAE Grade 3) due to prior cancer therapy.
- Participation in an interventional, investigational study within 2 weeks or 5 half-lives, whichever is shorter, of the first dose of study treatment.
- Any medical condition that would, in the Investigator's judgment, prevent the subject's participation in the clinical study due to safety concerns, compliance with clinical study procedures, or interpretation of study results.
- Pregnant or lactating women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin laboratory test.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (BR101801): Phase Ia (dose escalation)
Patients will receive BR101801 capsules orally, QD in 28-day cycles.
The regimen may be changed to BID dosing based on emerging data.
|
Phase Ia (dose escalation):25 mg capsules and 100 mg capsules Planned doses are 50, 100, 200, 325, and 450 mg.
|
Experimental: Treatment (BR101801):Phase Ib (dose expansion)
• Subjects with PTCL NOS, PTCL AITL, Nodal PTCL with TFH and PTCL FTCL
|
Phase Ib (dose expansion):25 and 100 mg capsules Doses administered will be determined from Phase Ia data.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determination of the MTD and RDE based on DLTs during Cycle 1 (Phase Ia )
Time Frame: From baseline to Week 4
|
The recommended dose is determined by the number of patients who experience a dose limiting toxicity (DLT).
|
From baseline to Week 4
|
Number of Participants With Adverse Events (AE) as a Measure of Safety and Tolerability of BR101801 when administered at the MTD or recommended dose (Phase Ia and Ib)
Time Frame: through study completion, and about average of 1 year
|
To evaluate safety and tolerability the aggregate review will include but is not limited to:
|
through study completion, and about average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax
Time Frame: Cycle1( each cycle is 28 days) Day 1 and Cycle 1( each cycle is 28 days) Day 15
|
Maximum concentration obtained directly from the observed concentration versus time data.
|
Cycle1( each cycle is 28 days) Day 1 and Cycle 1( each cycle is 28 days) Day 15
|
AUC(0-inf)
Time Frame: Cycle1( each cycle is 28 days) Day 1
|
Area under the plasma concentration-time curve from time zero extrapolated to infinity, calculated by linear up/log down trapezoidal summation
|
Cycle1( each cycle is 28 days) Day 1
|
AUC(0-last)
Time Frame: Cycle1( each cycle is 28 days) Day 1 and Cycle 1( each cycle is 28 days) Day 15, Pre-dose to 24 hours after dosing
|
Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration
|
Cycle1( each cycle is 28 days) Day 1 and Cycle 1( each cycle is 28 days) Day 15, Pre-dose to 24 hours after dosing
|
AUC(0-tau)
Time Frame: Cycle1( each cycle is 28 days) Day 1 and Cycle 1( each cycle is 28 days) Day 15, dosing interval: 24 or 12 hours
|
Area under the plasma concentration-time curve from time zero during a dosing interval
|
Cycle1( each cycle is 28 days) Day 1 and Cycle 1( each cycle is 28 days) Day 15, dosing interval: 24 or 12 hours
|
Ae
Time Frame: Cycle 1( each cycle is 28 days)Day 15, Pre-dose to 12 hours for BID dosing and Pre-dose to 24 hours for QD dosing
|
Cumulative amount of unchanged drug excreted in urine
|
Cycle 1( each cycle is 28 days)Day 15, Pre-dose to 12 hours for BID dosing and Pre-dose to 24 hours for QD dosing
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: TM Kim, M.D, Ph.D, Seoul National University Hospital
- Principal Investigator: SJ Kim, M.D, Ph.D, Samsung Medical Center
- Principal Investigator: DH Yoon, M.D, Ph.D, Asan Medical Center
- Principal Investigator: Jorge Chaves, M.D, Ph.D, Northwest Medical Specialities, PLLC
- Principal Investigator: Emily Curran, M.D, Ph.D, University of Cincinnati
- Principal Investigator: JS Kim, M.D, Ph.D, Severance Hospital, Yonsei University Health System
- Principal Investigator: EY Lee, M.D, M.S, National Cancer Center
- Principal Investigator: JO Lee, M.D, Ph.D, Seoul National University Bundang Hospital
- Principal Investigator: DH Yang, M.D, Ph.D, Chonnam National University Hospital
- Principal Investigator: WS Lee, M.D, Ph.D, Inje University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Neoplasms by Site
- Disease Attributes
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Neoplasms, Plasma Cell
- Leukemia, B-Cell
- Lymphoma, T-Cell
- Chronic Disease
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Hematologic Neoplasms
- Leukemia
- Waldenstrom Macroglobulinemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Lymphoma, T-Cell, Peripheral
Other Study ID Numbers
- BR-101801-CT-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Follicular Lymphoma
-
Joseph TuscanoNational Cancer Institute (NCI); Genentech, Inc.; Pharmacyclics LLC.RecruitingAnn Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
National Cancer Institute (NCI)TerminatedStage III Grade 1 Follicular Lymphoma | Stage III Grade 2 Follicular Lymphoma | Stage III Grade 3 Follicular Lymphoma | Stage IV Grade 1 Follicular Lymphoma | Stage IV Grade 2 Follicular Lymphoma | Stage IV Grade 3 Follicular LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterFox Chase Cancer Center; Pharmacyclics LLC.TerminatedFollicular Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade IIIaUnited States
-
Olivia Newton-John Cancer Research InstituteBristol-Myers Squibb; Barwon Health; Austin Health; Eastern Health; Fiona Stanley... and other collaboratorsRecruitingFollicular Lymphoma Stage II | Follicular Lymphoma Stage III | Follicular Lymphoma Stage IVAustralia
-
Robert LowskyNational Cancer Institute (NCI); Janssen, LP; The Leukemia and Lymphoma Society; Rising Tide FoundationCompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Fondazione Italiana Linfomi ONLUSCompletedFollicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade 3AItaly
-
Massachusetts General HospitalTG TherapeuticsActive, not recruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
National Cancer Institute (NCI)Celgene CorporationActive, not recruitingAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGrade 3a Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 3 Follicular Lymphoma | Ann Arbor Stage...United States
Clinical Trials on BR101801 (Phase Ia)
-
Immatics Biotechnologies GmbHBristol-Myers SquibbRecruitingCancer | Solid Tumor, Adult | Refractory Cancer | Recurrent CancerGermany
-
Immatics Biotechnologies GmbHRecruitingCancer | Solid Tumor, Adult | Refractory Cancer | Recurrent CancerGermany
-
Shanghai Hansoh Biomedical Co., LtdRecruitingAdvanced Solid TumorChina
-
Centre Hospitalier Universitaire de NiceRecruiting
-
University of FloridaPrometheus LaboratoriesCompletedInflammatory Bowel Disease | Glycogen Storage Disease Type IaUnited States
-
Azienda Ospedaliera San Giovanni BattistaCentro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte; Rete...Unknown
-
Université de SherbrookeRecruitingGlioblastoma Multiforme | RelapseCanada
-
Minghui Pharmaceutical Pty LtdNot yet recruitingRheumatoid Arthritis | Atopic Dermatitis
-
Institute for Neurodegenerative DisordersUnited States Department of DefenseCompletedParkinson DiseaseUnited States